Valuation : Bolt Biotherapeutics, Inc.

Market Cap 7.35M 6.33M 5.94M 5.42M 10.21M 702M 10.24M 70.44M 27.48M 355M 27.59M 26.99M 1.18B P/E 2026 *
-0.16x
P/E 2027 * -0.19x
Enterprise Value 7.35M 6.33M 5.94M 5.42M 10.21M 702M 10.24M 70.44M 27.48M 355M 27.59M 26.99M 1.18B EV / Sales 2026 *
36.7x
EV / Sales 2027 * 2.1x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 week+1,789.73%
1 month+1,542.98%
3 months+1,116.65%
6 months+815.29%
Current year+928.99%
1 week 4.97
Extreme 4.97
99.4
1 month 4.92
Extreme 4.92
99.4
3 years 4.92
Extreme 4.92
99.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2024-05-14
Chief Executive Officer 55 2024-05-14
Chief Operating Officer 61 2024-05-14
Director TitleAgeSince
Director/Board Member 64 2020-11-30
Director/Board Member 55 2024-05-14
Chairman 56 2024-09-03
Change 5-day change 1-year change 3-year change Capi.($)
-4.61%+1,789.73%+629.81%+167.20% 7.35M
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -2.02%-1.93%+116.36%+189.89% 31.33B
Weighted average by Cap. -1.93%-1.50%+57.17%+152.82%

Financials

2026 *2027 *
Net sales 200K 172K 162K 148K 278K 19.11M 279K 1.92M 748K 9.65M 751K 735K 31.99M 3.5M 3.02M 2.83M 2.58M 4.86M 335M 4.88M 33.55M 13.09M 169M 13.14M 12.85M 560M
Net income -47.4M -40.84M -38.3M -34.96M -65.86M -4.53B -66.07M -454M -177M -2.29B -178M -174M -7.58B -47.5M -40.93M -38.38M -35.03M -66M -4.54B -66.21M -455M -178M -2.29B -178M -174M -7.6B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.815USD
Average target price
29.00USD
Spread / Average Target
+660.16%

Quarterly revenue - Rate of surprise